Last reviewed · How we verify

NCT03704701: TICKER

The Interrogation of the Cardiomyopathy of Chronic Kidney Disease With advancEd caRdiac Imaging

Terminated Last updated 21 February 2022
What this trial tests

trial testing Cardiac MRI and contrast-enhanced cardiac CT in Chronic Kidney Diseases in 28 participants. Terminated before completion.

Timeline
10 October 2018
Primary endpoint
5 August 2020
5 August 2020

Quick facts

Lead sponsorNHS Greater Glasgow and Clyde
StatusTerminated
Study typeOBSERVATIONAL
Enrollment28
Start date10 October 2018
Primary completion5 August 2020
Estimated completion5 August 2020
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

NHS Greater Glasgow and Clyde — full company profile →

Who can join

Adults 40 to 100, any sex, with Chronic Kidney Diseases or Cardiomyopathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with kidney failure have a much higher risk of heart disease compared to people of the same age without kidney failure. The reason for this is not fully understood. In this project we will use Cardiac MRI (CMR), which is a very detailed scan of the heart and blood vessels, to try to better understand the cardiovascular changes that occur in kidney failure. We will perform CMR scans in 30 patients before and after dialysis (a treatment for patients with kidney failure) to see whether dialysis changes the heart muscle. The same patients will also undergo another type of heart scan, called a CT scan. This will allow us to compare the pictures from the 2 different types of scan to help us better understand any damage to the heart muscle that is present. Finally, we will test a new way to measure hardening of blood vessels on CMR. These three studies will help us to better understand the heart and blood vessel changes that happen in kidney failure. This research will also be useful for patients without kidney failure. We hope to be able to use it in the future to see which new treatments might be able to reduce the risk of heart disease in patients with kidney failure.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Myocardial changes on 3T cardiovascular magnetic resonance imaging in response to haemodialysis with fluid removal.
    Rankin AJ, Mangion K, Lees JS, Rutherford E, et al · · 2021 · cited 11× · PMID 34758850 · DOI 10.1186/s12968-021-00822-4
  2. Clinical Significance of Extracellular Volume of Myocardium (ECV) Assessed by Computed Tomography: A Systematic Review and Meta-Analysis.
    Martuszewski A, Paluszkiewicz P, Poręba R, Gać P. · · 2025 · cited 5× · PMID 40142874 · DOI 10.3390/jcm14062066
  3. Cardiovascular magnetic resonance for the detection of descending thoracic aorta calcification in patients with end-stage renal disease.
    Edy E, Rankin AJ, Lees JS, Barrientos PH, et al · · 2021 · cited 1× · PMID 34162405 · DOI 10.1186/s12968-021-00769-6
  4. The relationship between native T1 and mortality in patients requiring maintenance haemodialysis, using cardiac magnetic resonance imaging.
    Adenwalla SF, Stannard RE, Rankin AJ, March DS, et al · · 2025 · PMID 41342697 · DOI 10.1016/j.jocmr.2025.101978

Verify or expand the search:

Other recruiting trials for Chronic Kidney Diseases

Currently open trials in the same condition.

Other NHS Greater Glasgow and Clyde trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03704701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing